Page 8 - TD-2-3

Tumor Discovery Targeted drug delivery systems for the treatment of tumors

(circulatory and lymphatic systems). It is estimated and biodegradable nanoengineered systems enable
that every year, approximately 10 million individuals precise release of therapeutics at cancerous sites and have
suffer from malignant tumors, and around 1.3 million found extensive applications in diagnosis and treatment.
of them succumb to the disease. Advanced medical and Vesicular systems have proven to be efficient vehicles for
pharmaceutical strategies, including surgical procedures, delivering natural antioxidants and phytochemicals due to
radiotherapy, chemotherapy, and targeted drug delivery their antiproliferative- and apoptosis-inducing properties.
systems, have contributed to a reduction in mortality rates In addition, solid lipid nanoparticles are preferred due
over the past 5 years. to their high payload efficiency and stability, even at
elevated body temperatures, making them suitable for
According to a report by the Personalized Medicine
Coalition report (2017–2023), the introduction of delivering therapeutics to treat brain tumors. Furthermore,
researchers have extensively explored repetitive branched
personalized medicine has proven to be a successful structured dendrimers for the treatment of inoperable
approach in oncology, constituting approximately 50% liver cancers. A significant percentage of systemically
of Food and Drug Administration-approved antitumor delivered therapeutics relies on transvascular processes
therapeutics. Malignant tumors, commonly referred to for permeating malignant solid tumors, although this
as cancers, exhibit six hallmarks, including the activation process is very slow and requires a high concentration
of the proliferative signaling pathway, the inhibition of gradient for successful penetration. Consequently, only a
growth suppressors, resistance to cell death, the acquisition small fraction of the drug reaches the target site, resulting
of replicative immortality, the promotion of angiogenesis, in poor bioavailability. It is important to consider that
and the facilitation of metastasis. These hallmarks play increasing the dosage may lead to potential toxicity. Several
pivotal roles in the development of tumors and cancer . biological barriers exist that restrict the transportation of
[2]
In a nutshell, tumor cells exhibit highly differentiated chemotherapeutics at systemic, organ, and cellular levels.
and disordered tissue structures, along with anomalous
vasculature compared to normal cells. The deprivation of 2. Biological barriers influencing tumor-
essential nutrients and oxygen supply results in increased targeted drug delivery systems
interstitial pressure within cells, leading to an acidic and
hypoxic environment. Hypoxia-inducible transcription The anatomy and physiology of both tumor and host cells
factors (hif1 and hif2) are implicated in promoting distant present inherent biological barriers that restrict the entry
metastasis and mediating the progression of tumor cells . of drug delivery systems. Therefore, to achieve effective
[3]
therapeutic results at the target site, it is imperative to
Moreover, disorganized tumor cells exhibit inefficiencies design drug delivery systems that are tailored to overcome
in proton efflux to the extracellular environment, leading the obstacles.
to a hypoxic environment that disrupts the regulation
of glycolysis, adenosine triphosphate (ATP) generation, 2.1. Systemic barriers
and lactate production. At the molecular-level, these Biodistribution and clearance represent two prominent
variations and alterations in the tumor’s architectural systemic barriers that pose challenges to nano-based drug
profile differentiate them from normal cells. Tumor cells delivery approaches, particularly in achieving efficient
exhibit remarkable efficiency in mass-producing a range delivery to the target site. These barriers encompass a
of factors, such as growth factors, transferrin, interleukins, range of structural and chemical processes that shield
cytokines, chemokines, proteases, and sugar moieties that ingested foreign substances from adverse pH conditions
play crucial roles in tumor progression. Over the past three and the immune system’s responses. The immune system,
decades, numerous successful strategies have emerged for including macrophages, plays a critical role as a barrier to
the treatment and management of tumors. These strategies active drug-loaded particles, swiftly removing them from
are developed on a deep understanding of the processes surrounding tissues and the circulatory system . Similarly,
[4]
involved in tumor genesis and the complex interplay first-pass metabolism can affect the therapeutic window of
with the tumor microenvironment. The development and drug delivery systems, particularly when targeting lung
formulation of efficient drug delivery systems, including cancer. Factors within the circulatory system, mucosal
polymeric nanocarriers, vesicular systems, and inorganic lining, basal membrane, and the intercellular gaps between
nanoparticles, have demonstrated their effectiveness as endothelial cells all play roles in determining the selective
targeted mechanisms for delivering therapeutics into localization of size-dependent drug delivery systems . For
[5]
intracellular organelles. These systems undergo successful instance, nanoparticles tend to accumulate more within
functionalization and surface modification, facilitating the larger gaps between endothelial cells and in areas
recognition by tumor cell receptors. These biocompatible with a discontinuous basal membrane in blood vessels,

Volume 2 Issue 3 (2023) 2 https://doi.org/10.36922/td.1356